Health-Related Quality of Life Outcomes in Patients with Resected Epidermal Growth Factor Receptor–Mutated Non–Small Cell Lung Cancer Who Received Adjuvant Osimertinib in the Phase III ADAURA Trial

PURPOSE: In the phase III ADAURA trial, adjuvant treatment with osimertinib versus placebo, with/without prior adjuvant chemotherapy, resulted in a statistically significant and clinically meaningful disease-free survival benefit in completely resected stage IB–IIIA EGFR-mutated (EGFRm) non–small ce...

Descripción completa

Detalles Bibliográficos
Autores principales: Majem, Margarita, Goldman, Jonathan W., John, Thomas, Grohe, Christian, Laktionov, Konstantin, Kim, Sang-We, Kato, Terufumi, Vu, Huu Vinh, Lu, Shun, Li, Shanqing, Lee, Kye Young, Akewanlop, Charuwan, Yu, Chong-Jen, de Marinis, Filippo, Bonanno, Laura, Domine, Manuel, Shepherd, Frances A., Atagi, Shinji, Zeng, Lingmin, Kulkarni, Dakshayini, Medic, Nenad, Tsuboi, Masahiro, Herbst, Roy S., Wu, Yi-Long
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for Cancer Research 2022
Materias:
Clinical Trials: Targeted Therapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9359973/
https://www.ncbi.nlm.nih.gov/pubmed/35012927
http://dx.doi.org/10.1158/1078-0432.CCR-21-3530

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9359973/
https://www.ncbi.nlm.nih.gov/pubmed/35012927
http://dx.doi.org/10.1158/1078-0432.CCR-21-3530

Ejemplares similares